{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "binds",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q9H0F6",
      "entity_text" : "SHARPIN",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ03281",
      "entity_text" : "HOIL-1L",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:10090" ],
      "TissueType" : [ "tissuelist:TS-0068" ],
      "Organ" : [ "uberon:UBERON:0000105" ]
    }
  },
  "verbose_text" : "In light of the involvement of LUBAC in the pathogenesis of B cell lymphomas and the resistance of cancers to immune checkpoint blockade therapy and cisplatin, our results sug gest that the abundance of LUBAC could be controlled by inhibiting the HOIL-1L / SHARPIN interaction.",
  "reading_complete" : "2020-08-08T11:50:38Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T11:48:10Z",
  "trigger" : "interaction",
  "evidence" : [ "HOIL-1L/SHARPIN interaction" ],
  "pmc_id" : "6044281",
  "score" : 0
}